Nonalcoholic fatty liver disease (NAFLD), affecting about 25% of general population and
more than 50% of dysmetabolic patients, is an emerging cause of chronic liver disease and …

Abstract Purpose of Review Obesity is accompanied by atherogenic dyslipidemia, a specific
lipid disorder characterized by both quantitative and qualitative changes of plasma …

Among the diseases causing human death, cardiovascular disease (CVD) remains number
one according to the World Health Organization report in 2021. It is known that …

Increased production and buildup of reactive oxygen species (ROS) can lead to various
health issues, including metabolic problems, cancers, and neurological conditions. Our …

(1) Background: Obesity is closely connected to the pathophysiology of cardiovascular
diseases (CVDs). Excess fat accumulation is associated with metabolic malfunctions that …

Disorders of lipoprotein metabolism and glucose homeostasis are common consequences
of insulin resistance and usually co-segregate in patients with metabolic syndrome and type …

Background The atherogenic index of plasma (AIP) and cardiovascular disease (CVD) in
participants with abnormal glucose metabolism have been linked in previous studies …

Background: Semaglutide is a recently approved glucagon-like peptide-1 receptor agonist.
Several trials reported the protective effect of injectable semaglutide on cardiovascular (CV) …

Background. Metabolic alterations, particularly disorders of lipoprotein metabolism in COVID‐
19, may affect the course and outcome of the disease. This study aims at evaluating the …

Oxidative stress is the consequence of an overproduction of reactive oxygen species (ROS)
that exceeds the antioxidant defense mechanisms. Increased levels of ROS contribute to the …